Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

Authors: Nosov D, Esteves B, Lipatov O, Lyulko A, Anischenko A, Chacko R, Doval D, Strahs A, Slichenmyer W, and Bhargava P JCO May 10, 2012:1678-1685; DOI:10.1200/JCO.2011.35.3524. Click here for link to article.

Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

Click Here To View Our ASCO Poster:

TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)